Narcolepsy
Clinical Snapshot
Narcolepsy is a chronic disorder characterized by excessive daytime sleepiness (EDS), caused by a deficiency of the orexin (hypocretin) neuropeptide that regulates wakefulness.[1] It affects roughly 1 in 2,000 people in Canada; global prevalence is estimated at 25-50 per 100,000, with typical onset during adolescence and a second, smaller peak at ages 30-39.[1]
Narcolepsy is classified into two types by the presence or absence of cataplexy. Type 1 narcolepsy (narcolepsy with cataplexy) often includes a pentad of excessive daytime sleepiness, cataplexy, sleep paralysis, hallucinations while falling asleep, and fragmented sleep — though not all five features need be present.[1] Type 2 narcolepsy lacks cataplexy entirely.[1] Of Canadians with narcolepsy, approximately 60-70% experience cataplexy on top of excessive daytime sleepiness.[1]
Type 1 narcolepsy is now understood mechanistically as an immune-mediated process: T-cell-driven destruction of the small population of hypocretin (orexin)-producing neurons in the lateral hypothalamus, strongly associated with the HLA subtype HLA-DQB1*06:02, which is present in over 90% of Type 1 cases.[2] This allele is also carried by a meaningful share of the general population, however, making it a necessary but not a sufficient cause on its own; infections are thought to contribute as a possible environmental trigger for the autoimmune process in genetically susceptible individuals.[2] Type 2 narcolepsy, by contrast, is not consistently associated with measurable hypocretin deficiency, and its underlying mechanism is less well defined.
The single highest-yield discrimination a pharmacist can make in this chapter is recognizing genuine cataplexy for what it is: brief, sudden loss of muscle tone, often focal to the face or hands, without loss of consciousness, triggered by emotion (classically laughter, but also anger, surprise, or elation).[1] Because consciousness is fully preserved throughout, cataplexy is genuinely distinct from a seizure (which produces impaired consciousness and a postictal state) and from syncope (which produces loss of consciousness) — a distinction that changes the entire workup if missed. Equally important: cataplexy is specific to Type 1 and is not present in every patient with narcolepsy, so its absence never rules the condition out.
Recognize the Condition
The pentad, and why most patients do not have all five features
Type 1 narcolepsy is classically taught as a pentad: excessive daytime sleepiness, cataplexy, sleep paralysis, hallucinations while falling asleep (hypnagogic) or waking (hypnopompic), and fragmented nocturnal sleep.[1] In practice, most patients present with excessive daytime sleepiness plus only some of the remaining features — waiting for a "complete" pentad before considering the diagnosis is a genuine source of missed or delayed recognition. Excessive daytime sleepiness is the one feature present in essentially all patients, in both types, and is usually the presenting complaint that first brings a patient to a pharmacy or primary care visit.
The five features, in clinical detail
Excessive daytime sleepiness
A persistent, day-long propensity to fall asleep, distinct from ordinary tiredness in that it is genuinely difficult to resist. Early on, this manifests as sleep attacks in sedentary or monotonous situations (reading, watching television, sitting in a meeting); as severity increases, sleep attacks intrude into active or even dangerous situations — eating, conversing, or driving. Naps are often brief and transiently refreshing, which is itself a useful, if imperfect, clinical clue.
Cataplexy
Brief, sudden loss of muscle tone, often focal to the face or hands, without loss of consciousness; episodes are triggered by emotion.[1] Episodes range from partial (jaw sagging, slurred speech, head drooping, buckling knees) to complete (full-body collapse), typically last seconds to about two minutes, and resolve spontaneously with tone fully restored. Deep tendon reflexes are characteristically absent during an episode. Laughter is the classic and most common trigger; anger, surprise, and elation are also recognized triggers.
Sleep paralysis
A transient inability to move or speak occurring at sleep onset or on waking, usually lasting seconds to a few minutes, and resolving spontaneously or with external touch/sound. It is frightening but benign, and — importantly for diagnostic reasoning — also occurs occasionally in the general population without narcolepsy, so on its own it is not diagnostic.
Hypnagogic and hypnopompic hallucinations
Vivid, often frightening visual, auditory, or tactile hallucinations occurring at the transition into sleep (hypnagogic) or out of it (hypnopompic), distinct from a primary psychiatric hallucinatory disorder by their specific timing at sleep transitions and their frequent co-occurrence with sleep paralysis.
Fragmented nocturnal sleep
A genuine paradox worth explaining to patients: despite profound daytime sleepiness, nighttime sleep in narcolepsy is often poor quality, with frequent awakenings — this is not simply "not enough sleep" and is not corrected by extending time in bed alone.
Type 1 versus Type 2 — the key distinguishing feature
| Feature | Type 1 (narcolepsy with cataplexy) | Type 2 (narcolepsy without cataplexy) |
|---|---|---|
| Cataplexy | Present (defining feature), though not necessarily from disease onset | Absent, by definition |
| Hypocretin/orexin | Typically deficient (CSF hypocretin-1 ≤110 pg/mL); underlying autoimmune, HLA-DQB1*06:02-associated destruction of hypocretin neurons | Usually normal or not consistently deficient |
| Excessive daytime sleepiness | Present | Present |
| Sleep paralysis / hallucinations | Common | Can occur, less specific |
Functional impact is real and often underappreciated: school and work performance decline, and relationship difficulties are common as the condition disrupts a patient's ability to stay engaged and alert through ordinary daily activities.[1]
Risk Factors
- HLA-DQB1*06:02 — present in over 90% of Type 1 narcolepsy cases, reflecting the disorder's autoimmune, T-cell-mediated basis, though this allele is also carried by a meaningful share of the general population and is therefore necessary but not sufficient on its own to cause disease.[2]
- An autoimmune process targeting hypocretin (orexin)-producing neurons in the lateral hypothalamus, with infection proposed as a possible environmental trigger in genetically susceptible individuals.[2]
- Adolescent onset is the typical pattern, with a second, smaller onset peak at ages 30-39 — a bimodal age distribution worth keeping in mind when a "first" presentation occurs later in adulthood.[1]
- A family history of narcolepsy modestly raises risk relative to the general population, though most cases are sporadic.
- Secondary (symptomatic) narcolepsy from a structural hypothalamic lesion, tumour, traumatic brain injury, or a paraneoplastic process is uncommon but real, and should be considered specifically when onset is abrupt, occurs outside the typical adolescent/young-adult age range, or is accompanied by other neurological findings.
- Rare genetic and metabolic disorders (for example, Niemann-Pick disease type C) can produce a cataplexy-like phenotype in children and should be kept in the differential for atypical paediatric presentations.
Red Flags & Refer
Any of the following changes the plan from "monitor" to "refer promptly, or counsel urgently on safety":
- Symptoms persisting beyond 3 months, or any episode of cataplexy at all — both are explicit referral thresholds to a sleep medicine physician, provided the symptoms are not otherwise explained by another sleep disorder, medications, substances, or a mood condition.[1]
- A patient who drives professionally, or operates heavy machinery, presenting with current excessive daytime sleepiness or any cataplexy, sleep attack, or sleep paralysis episode in the past 12 months — driving all classes of motor vehicle is prohibited in this situation, with or without treatment, until 12 months of sustained symptom control is achieved; commercial driving carries additional, stricter restrictions given the difficulty of long-distance driving without significant hypersomnolence (see Special Populations and Monitoring & Follow-up).[3][1]
- A dramatic-looking episode of collapse or unresponsiveness being worked up as a seizure or a faint without a directed history for cataplexy — consciousness is fully preserved in cataplexy, and missing this distinction sends the workup in the wrong direction entirely.[1]
- New or worsening depression, suicidal ideation, or a marked mood change in a patient on sodium oxybate, the lower-sodium oxybate salts, or a wake-promoting/stimulant agent — a genuine, monitored safety signal for these drug classes, not simply "the underlying condition" (see Special Populations and Monitoring & Follow-up).[4][5]
- New chest pain, palpitations, syncope, or uncontrolled hypertension in a patient on any wake-promoting agent or stimulant — a cardiovascular evaluation is warranted before continuing therapy.[5][6][7]
- Abrupt-onset excessive daytime sleepiness or cataplexy-like symptoms outside the typical adolescent/young-adult age range, or accompanied by other neurological findings — raises concern for a secondary, structural cause and warrants neuroimaging and specialist referral rather than routine narcolepsy management.
Assessment & Diagnosis
Narcolepsy requires objective sleep testing
Unlike several other conditions in this guideline library, narcolepsy is not diagnosed on history and examination alone. Multiple Sleep Latency Testing (MSLT) is the first-line diagnostic test, conducted the day after an overnight polysomnography (PSG).[1] The overnight PSG first excludes another primary sleep disorder (particularly obstructive sleep apnea) and confirms adequate total sleep time, so that a short MSLT sleep latency the next day genuinely reflects narcolepsy rather than untreated sleep-disordered breathing or sleep deprivation.
The MSLT protocol
The MSLT includes 5 monitored daytime nap opportunities, scheduled 2 hours apart, assessing the patient's propensity to fall asleep and to enter REM sleep abnormally quickly during a nap.[1] A short mean sleep latency across the naps, together with 2 or more sleep-onset REM periods (a REM period beginning within about 15 minutes of falling asleep, well before REM would normally occur), supports the diagnosis; one of the required sleep-onset REM periods may be substituted by a sleep-onset REM period observed on the preceding overnight PSG.
Cerebrospinal fluid hypocretin-1
Where lumbar puncture is performed (typically at a dedicated sleep or neurology centre rather than as a routine primary-care test), a CSF hypocretin-1 concentration of 110 pg/mL or lower is diagnostic for Type 1 narcolepsy and can be particularly useful when MSLT results are equivocal or when a patient cannot safely discontinue an interfering medication before testing.[2]
Before testing: exclude the mimics
A 1-2 week period of actigraphy or a sleep diary before PSG/MSLT helps exclude chronic insufficient sleep, which can itself produce a short MSLT latency and false-positive-appearing results. Directly relevant differential diagnoses to screen for and exclude before attributing excessive daytime sleepiness to narcolepsy include: insufficient sleep syndrome, obstructive sleep apnea, a circadian rhythm disorder (including shift work disorder), medication- or substance-induced hypersomnolence (sedating drugs, alcohol, cannabis), a mood disorder, and idiopathic hypersomnia (typically longer, less refreshing naps, without cataplexy and with fewer or no sleep-onset REM periods on MSLT).[1]
Confirming the type
Once the diagnosis of narcolepsy is confirmed, Type 1 versus Type 2 is distinguished by the presence or absence of cataplexy and, where measured, by CSF hypocretin-1.[2] This distinction matters directly for treatment selection, since the only Health Canada-approved cataplexy-specific therapies (sodium oxybate and the lower-sodium oxybate salts) are indicated for cataplexy, which by definition only Type 1 patients have.
Treatment Targets
- Reduce excessive daytime sleepiness enough to allow safe, functional daily activity at school, at work, and — once sustained control is demonstrated — behind the wheel.
- Control cataplexy to prevent physical injury from sudden falls and to reduce the real psychosocial burden of unpredictable, emotion-triggered episodes.
- Consolidate fragmented nocturnal sleep, since poor-quality nighttime sleep both worsens daytime symptoms and is itself a distinct, treatable target for some agents (notably the oxybates).
- Address sleep paralysis and hypnagogic/hypnopompic hallucinations when they are frequent or distressing enough to warrant treatment in their own right.
- Treat narcolepsy as the lifelong condition it is — with treatment, many patients regain near-normal function, but ongoing therapy and periodic reassessment, not a fixed one-time regimen, is the expectation.{C(cmaj)}
- Enable safe return to driving once genuinely sustained symptom control is demonstrated, and counsel proactively before that point (see Special Populations).
- Recognize and manage psychiatric and mood comorbidity, both as part of the condition itself and as a genuine adverse effect of some therapies.
- Minimize medication-related harms specific to this drug class: cardiovascular risk from stimulants and wake-promoting agents, abuse/diversion potential and restricted-distribution requirements for the oxybates, and unplanned pregnancy risk from the contraceptive-efficacy interaction shared by several agents in this chapter.
Choose Initial Treatment
Classify the dominant symptom, then choose from the agents proven for that symptom
Excessive daytime sleepiness (EDS) is the dominant or only symptom a wake-promoting agent — modafinil or solriamfetol — is first-line; both carry a strong recommendation from the American Academy of Sleep Medicine.[8] Cataplexy is present, regardless of EDS severity sodium oxybate, or the lower-sodium oxybate salts, is first-line; in Canada, both are Health Canada-approved specifically for cataplexy, not for excessive daytime sleepiness — a genuine difference from US labelling that changes how these drugs should be discussed with patients here.[4][9] EDS not adequately controlled by a wake-promoting agent alone, in a Type 1 patient sodium oxybate/lower-sodium oxybate salts also meaningfully improve EDS and disrupted nocturnal sleep in practice, even though the Canadian indication is specifically cataplexy, making them a reasonable next step before adding a second wake-promoting agent.
Excessive daytime sleepiness
First-line modafinil 200 mg/day, divided into a morning and a noon dose, titrated by 100 mg increments to a usual maximum of 400 mg/day; the second dose should generally be taken no later than early afternoon to minimize insomnia risk.[5] Modafinil has no significant effect on cataplexy — do not select it expecting cataplexy benefit.[5] First-line alternative solriamfetol 75 mg once daily on awakening, doubled after at least 3 days to a maximum of 150 mg/day if needed and tolerated; avoid dosing within 9 hours of planned bedtime.[6] Not marketed in Canada armodafinil, the R-enantiomer of modafinil, carries a conditional AASM recommendation and may appear on a cross-border or transferred prescription, but is not available through a Canadian pharmacy and is contraindicated as a hypersensitivity risk in patients who cannot tolerate modafinil.[8][5] Conditional recommendation, older stimulant class methylphenidate or dextroamphetamine, both genuinely indicated for narcolepsy on their current Canadian product monographs (not merely for ADHD), individualized from a low starting dose and titrated to effect, with meaningfully greater cardiovascular and abuse-potential burden than modafinil or solriamfetol.[7][10][8]
Cataplexy
First-line, Health Canada-approved specifically for cataplexy sodium oxybate, starting at 4.5 g/night divided into two equal doses of 2.25 g (the first at bedtime, the second 2.5-4 hours later), titrated in 1.5 g/night increments to a maximum of 9 g/night, with 2-week intervals recommended between dose changes; up to 8-10 weeks of therapy may be needed before a maximal cataplexy response is seen, so avoid judging this drug too early.[4] Preferred where sodium intake is a concern the lower-sodium oxybate salts (calcium, magnesium, potassium, and sodium oxybates), containing the same active moiety (oxybate/GHB) but with approximately 92% less sodium than sodium oxybate at an equivalent dose — the same twice-nightly dosing scheme applies, starting at 4.5 g/night and titrated to a maximum of 9 g/night, with 1-week (rather than 2-week) intervals generally recommended between titrations.[9] Patients transitioning from sodium oxybate to the lower-sodium salts are initiated at the same gram-for-gram dose and adjusted from there based on response and tolerability.[9] Required before starting either oxybate enrollment of the prescriber, the pharmacy, and the patient in the manufacturer's Controlled Distribution Program (the same program covers both products, administered through Innomar Strategies) — see Special Populations and Monitoring & Follow-up for what this involves in practice.[4][9] Off-label alternative, particularly where rapid onset or lower regulatory burden is a priority venlafaxine or clomipramine are widely used in practice for cataplexy given their much faster onset than sodium oxybate, though the AASM guideline made no formal recommendation for the SSRI/SNRI class specifically, citing insufficient/inconclusive trial-level evidence — individualize and set expectations accordingly rather than presenting these as equivalent, evidence-graded alternatives to the oxybates.[8]
Pitolisant — a genuine option with a real Canadian access barrier
Pitolisant is an oral histamine H3-receptor antagonist/inverse agonist that increases histaminergic neurotransmission to promote wakefulness, and is the only agent in this chapter with a formal Health Canada indication for both excessive daytime sleepiness and cataplexy.[11] It carries a strong AASM recommendation.[8] However, the CDA-AMC (CADTH) Canadian Drug Expert Committee reviewed pitolisant in December 2022 and recommended it not be reimbursed by Canadian public drug plans: two double-blind, randomized, controlled comparative trials (HARMONY I and HARMONY Ibis) failed to demonstrate that pitolisant was at least as good as modafinil for excessive daytime sleepiness, and while pitolisant did reduce weekly cataplexy episodes versus placebo in the HARMONY CTP trial (2.27 versus 4.51 episodes/week), results were inconsistent across trials and the committee could not conclude the drug met identified patient priorities given these limitations.[11] At an estimated annual cost of roughly $6,074 to $12,147 per patient, discuss this real access and cost barrier with patients directly before recommending pitolisant as a first choice in Canada.[11]
Non-Pharmacologic Treatment
- Scheduled naps — brief, strategically timed naps (for example, two to three 15-20 minute naps at predictable points in the day) are widely used in practice as an adjunct to pharmacotherapy, though the AASM guideline made no formal recommendation on scheduled naps specifically, citing insufficient evidence to grade the practice — present this as a reasonable, low-risk adjunct rather than an evidence-graded standalone therapy.[8]
- Sleep hygiene and a consistent sleep-wake schedule — adequate, regular nocturnal sleep duration reduces the severity of daytime symptoms; sleep deprivation from any cause tends to worsen both excessive daytime sleepiness and cataplexy frequency.
- Patient and family/school/employer education is itself part of treatment — helping the people around a patient understand that cataplexy is involuntary and that sleep attacks are not a matter of willpower reduces stigma and improves safety planning.[1]
- Avoid alcohol and other sedating substances, which worsen excessive daytime sleepiness and are also specifically contraindicated in combination with sodium oxybate/the lower-sodium oxybate salts (see Pharmacologic Treatment Options and Special Populations).
- Regular exercise and weight management support overall alertness and cardiovascular health, which is particularly relevant given the cardiovascular considerations of several narcolepsy drug classes.
- Proactive safety planning around cataplexy triggers — avoiding known high-risk activities (for example, driving, swimming alone, or operating machinery) during a period of poor cataplexy control, and counseling on how to respond safely if an episode occurs.
- Psychological support or counselling for the genuine psychosocial impact of narcolepsy — school/work performance decline and relationship strain are recognized consequences, not incidental complaints.[1]
Special Populations
Pregnancy and reproductive potential
Modafinil is contraindicated in pregnancy based on post-marketing reports, modafinil may cause fetal harm; pregnancy registry data documented major congenital anomalies (including cardiac anomalies) at a higher prevalence than background rates among infants exposed in utero.[5] A negative pregnancy test is required before starting modafinil in a patient of reproductive potential.[5] A genuinely important, easily missed interaction modafinil, armodafinil, and pitolisant may each reduce the effectiveness of steroidal (hormonal) contraceptives via CYP3A4/5 induction — advise effective non-hormonal or alternative contraception during treatment and for 2 months after stopping modafinil specifically.[5][8] Sodium oxybate and the lower-sodium oxybate salts have limited human pregnancy data; weigh benefit against risk with the prescriber and avoid use where feasible. Stimulants (methylphenidate, dextroamphetamine) should be used at the lowest effective dose in pregnancy, in direct consultation with the prescriber, given limited dedicated safety data for this specific indication.
Children and adolescents
Onset commonly occurs during adolescence, so paediatric presentations are genuinely expected, not rare.[1] In Canada, neither sodium oxybate nor the lower-sodium oxybate salts is authorized for pediatric use — no data are available to Health Canada for patients under 18, in contrast to their approved pediatric use in some other jurisdictions.[4][9] Modafinil is likewise not authorized for pediatric use in Canada.[5] Methylphenidate and dextroamphetamine both carry a genuine, current Canadian narcolepsy indication and are used under specialist care in children old enough for the specific product's approved age range, individualized and titrated cautiously given the class's cardiovascular and psychiatric monitoring requirements.[7][10]
Older adults
There is very limited experience with sodium oxybate and the lower-sodium oxybate salts in patients 65 years and older; start at the low end of the dosing range and monitor closely for impaired motor and cognitive function.[4][9] Modafinil elimination is reduced with aging — use lower doses.[5] Stimulant cardiovascular risk (hypertension, arrhythmia) becomes more consequential as baseline cardiovascular disease prevalence rises with age.
Hepatic impairment
Sodium oxybate and the lower-sodium oxybate salts: start at one-half the usual dose, divided into two doses, in patients with hepatic impairment.[4][9] Modafinil: reduce the dose by one-half in severe hepatic impairment.[5]
Renal impairment
Sodium oxybate and the lower-sodium oxybate salts require no dose adjustment for renal impairment (less than 5% of sodium oxybate is renally excreted), though no studies have been conducted in renal failure and the sodium load of standard sodium oxybate is a separate, real consideration in significant renal impairment.[4][9] Solriamfetol requires meaningful renal dose adjustment: mild impairment (creatinine clearance 60-89 mL/min) needs no adjustment; moderate impairment (30-59 mL/min) starts at 37.5 mg/day, increasing to a 75 mg/day maximum after 7 days if tolerated; severe impairment (15-29 mL/min) is limited to a 37.5 mg/day maximum, used only if benefit is judged to outweigh risk; end-stage renal disease (below 15 mL/min) is a contraindication.[6]
Cardiovascular disease
Modafinil requires a baseline cardiac evaluation, including an ECG, before starting, particularly with coronary artery disease, a recent MI, or unstable angina; monitor blood pressure and heart rate through treatment and discontinue if arrhythmia or moderate-to-severe hypertension develops.[5] Solriamfetol is contraindicated with an MI within the past year, unstable angina, uncontrolled hypertension, or serious cardiac arrhythmias; blood pressure and heart rate should be controlled and monitored before and during treatment.[6] Methylphenidate is contraindicated in moderate-to-severe hypertension and significant structural cardiac disease.[7] Standard sodium oxybate's real sodium load (up to roughly 1,638 mg of sodium at the 9 g/night maximum dose) is a specific reason to prefer the lower-sodium oxybate salts in patients with hypertension, heart failure, or salt-restricted diets.[4][9]
MAOI use
Solriamfetol, methylphenidate, and dextroamphetamine are each contraindicated with concurrent MAOI use or within 14 days of stopping an MAOI, given the risk of a hypertensive crisis.[6][7][10]
History of substance use disorder
Oxybate is gamma-hydroxybutyrate (GHB), a substance with genuine, known abuse potential; evaluate patients for a history of drug abuse before prescribing, and monitor closely for signs of misuse (dose escalation on the patient's own initiative, drug-seeking behaviour).[4][9] Stimulants carry a parallel caution, and combining modafinil with another CNS stimulant (amphetamines, methylphenidate) can produce additive blood pressure/heart rate increases and, specifically with dextroamphetamine, clinically important QTc prolongation — these combinations should not be taken at the same time.[5]
Monitoring & Follow-Up
Track functional outcome directly at every visit — the patient's actual ability to stay awake and engaged at school, at work, and while driving — not only a symptom count, since this is the outcome that determines both quality of life and driving eligibility.[1]
For cataplexy on sodium oxybate or the lower-sodium oxybate salts: keep a cataplexy frequency diary and allow a full 8-10 weeks at an adequate, tolerated dose before judging maximal response.[4] Monitor specifically for confusion (reported in a meaningful minority of treated patients, usually resolving with continued treatment or dose adjustment), for emergent depressive symptoms or suicidal ideation — a labelled concern, particularly in patients with a prior history of depression — and for parasomnia/sleepwalking and nocturnal urinary or fecal incontinence, all of which are recognized, dose-related adverse effects that should prompt evaluation rather than being dismissed as unrelated.[4]
Patients on sodium oxybate or the lower-sodium oxybate salts should be seen regularly through the course of therapy — every 3 months is the interval recommended under the Controlled Distribution Program — with serious adverse events reported to the manufacturer as part of that program.[4]
Monitor blood pressure and heart rate at initiation and periodically during treatment with modafinil, solriamfetol, methylphenidate, or dextroamphetamine, with closer monitoring in patients with any cardiovascular risk factor or renal impairment (solriamfetol specifically).[5][6][7]
Driving fitness is an ongoing, not a one-time, assessment. A diagnosis of narcolepsy supported by a sleep study and MSLT is required before driving recommendations apply; driving all classes of motor vehicle is prohibited with any uncontrolled cataplexy, sleep attack, or sleep paralysis episode in the past 12 months, with or without treatment.[3] Commercial driving carries a further caution, since long-distance driving is genuinely difficult without significant hypersomnolence; limited exceptions exist for short-route daytime driving in patients maintaining a regular sleep-wake cycle.[3] Higher crash probability correlates with younger age, elevated subjective sleepiness scores, and concurrent psychiatric conditions — factors worth specifically asking about at follow-up.[3] With sustained, effective treatment, many patients regain near-normal function and become eligible to drive once symptoms have been controlled for 12 months.[1]
Common Errors to Avoid
- Assuming narcolepsy means only "falls asleep at random moments" and never asking specifically about triggered muscle weakness — many patients do not spontaneously volunteer cataplexy or even recognize it as part of the same condition.[1]
- Diagnosing or ruling out narcolepsy from history and examination alone, without objective PSG-then-MSLT confirmation.[1]
- Working up a dramatic cataplexy episode as a seizure or a faint because consciousness appears altered — it is fully preserved in cataplexy, and this is the key distinguishing feature.[1]
- Prescribing or expecting modafinil to help cataplexy — its Canadian label states explicitly that it has no significant effect on cataplexy.[5]
- Forgetting the contraceptive-efficacy interaction shared by modafinil, armodafinil, and pitolisant — an entirely preventable unplanned-pregnancy risk that pharmacist counseling should specifically address.[5][8]
- Starting or transferring a prescription for sodium oxybate or the lower-sodium oxybate salts without confirming enrollment of the prescriber, pharmacy, and patient in the Controlled Distribution Program, or dispensing outside the single-wholesaler restricted-distribution chain.[4][9]
- Co-dispensing or overlooking concurrent use of sodium oxybate/the lower-sodium oxybate salts with another sedative-hypnotic, opioid, or alcohol — an absolute contraindication given additive CNS and respiratory depression risk.[4]
- Not counseling on the mandatory oxybate administration routine: take only at bedtime, do not walk around after dosing, prepare and take the second dose 2.5-4 hours later while already in bed, and avoid hazardous activity or driving for at least 6 hours after a dose.[4]
- Overlooking that food significantly reduces oxybate bioavailability — a dose taken too close to a meal changes both efficacy and predictability of effect; patients should stop eating at least 2 hours before the first dose.[4]
- Assuming standard sodium oxybate and the lower-sodium oxybate salts are interchangeable without adjustment for sodium-sensitive comorbidity, when the entire point of the lower-sodium formulation is to avoid that exact problem.[9]
- Recommending pitolisant as a routine first choice in Canada without mentioning the real, documented non-reimbursement decision and cost.[11]
- Skipping the driving-fitness conversation — a patient with current or recent symptoms should be counseled proactively, not only after an incident.[3]
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Wake-Promoting Agents and Stimulants for Excessive Daytime Sleepiness
Modafinil and solriamfetol are first-line, strongly recommended options with the lowest abuse-potential and cardiovascular burden of this group; methylphenidate and dextroamphetamine carry a genuine, current Canadian narcolepsy indication but a conditional recommendation and meaningfully greater cardiovascular/abuse-potential burden.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Modafinil | Initial: 200 mg/day, divided AM and noon Titration: Increase in 100 mg increments as needed/tolerated Usual maximum: 400 mg/day; single doses ≥300 mg or totals >400 mg not recommended | Headache, nausea, nervousness, insomnia, anxiety, dizziness; rare serious/multi-organ cutaneous reactions | Reduces effectiveness of steroidal contraceptives (CYP3A4/5 induction); reduces cyclosporine levels; caution with other CNS stimulants (additive BP/HR effects; QTc prolongation specifically reported with dextroamphetamine co-administration) | No significant effect on cataplexy; baseline ECG recommended, particularly with cardiac risk factors; contraindicated in pregnancy |
| Solriamfetol | Initial: 75 mg once daily on awakening Titration: May double to 150 mg/day after ≥3 days Administration: Avoid dosing within 9 hours of planned bedtime | Headache, nausea, decreased appetite, anxiety, increased blood pressure/heart rate | Contraindicated with MAOIs (within 14 days) due to hypertensive crisis risk; caution with other drugs that raise blood pressure/heart rate | Contraindicated with MI in the past year, unstable angina, uncontrolled hypertension, serious arrhythmias, or end-stage renal disease; renal dose adjustment required |
| Armodafinil | Canadian availability: None — not authorized for sale | Same class effects as modafinil | Same interaction profile as modafinil | Not marketed in Canada; conditional AASM recommendation; recognize the class but it cannot be dispensed here |
| Methylphenidate | Adults: Individualized, low starting dose; titrate to effect, typically in the 10-60 mg/day range divided across morning/midday doses | Nervousness, insomnia, decreased appetite, tachycardia, hypertension, dyskinesia | Contraindicated with MAOIs (within 14 days); may antagonize antihypertensives; caution with other dopaminergic/serotonergic drugs | Genuine, current Canadian narcolepsy indication; contraindicated in moderate-to-severe hypertension and significant structural cardiac disease; genuine abuse-potential burden |
| Dextroamphetamine | Adults and adolescents ≥12 years: Start 10 mg/day; increase in 10 mg increments at weekly intervals Usual range: 5-60 mg/day depending on individual response | Insomnia, anorexia, tachycardia, hypertension, irritability, tics | Contraindicated with MAOIs (within 14 days); caution with other sympathomimetics and CNS stimulants | Genuine, current Canadian indication for adjunctive treatment of narcolepsy; contraindicated in cardiovascular disease, hyperthyroidism, and glaucoma |
Oxybates for Cataplexy (Canadian Indication: Cataplexy, Not EDS)
Both products contain the same active moiety (oxybate/gamma-hydroxybutyrate, GHB) and share an identical Controlled Distribution Program; the lower-sodium formulation exists specifically to reduce cardiovascular/renal sodium burden without sacrificing efficacy.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Sodium oxybate | Initial: 4.5 g/night, divided into two 2.25 g doses 2.5-4 h apart Titration: Increase/decrease by 1.5 g/night (0.75 g/dose) at ≥2-week intervals Maximum: 9 g/night; doses above 9 g/night not studied and not recommended Hepatic impairment: Start at one-half the usual dose | Confusion, nausea, dizziness, nocturnal urinary/fecal incontinence, sleepwalking, depression/emergent suicidality (monitor closely, especially with a prior depression history) | Contraindicated with alcohol, sedative-hypnotics, or other CNS depressants (respiratory depression/death risk); divalproex sodium increases oxybate exposure (reduce oxybate dose by ≥20% if co-starting); topiramate co-administration associated with increased GHB concentration | Health Canada indication is cataplexy specifically; requires Controlled Distribution Program enrollment; food significantly reduces bioavailability — dose ≥2 hours after eating; 8-10 weeks for maximal cataplexy response |
| Calcium, magnesium, potassium, and sodium oxybates | Initial: 4.5 g/night, divided into two 2.25 g doses 2.5-4 h apart Titration: Increase/decrease by 1.5 g/night at ≥1-week intervals Maximum: 9 g/night; doses above 9 g/night not studied and not recommended Hepatic impairment: Start at one-half the usual dose | Same class effects as sodium oxybate | Same interaction profile as sodium oxybate, including the divalproex sodium dose-reduction requirement | Approximately 92% lower sodium than sodium oxybate at an equivalent dose; same Health Canada cataplexy-specific indication and Controlled Distribution Program; patients switching from sodium oxybate start gram-for-gram |
Pitolisant — EDS and/or Cataplexy
The only agent in this chapter with a formal Health Canada indication for both excessive daytime sleepiness and cataplexy; discuss the real, current Canadian non-reimbursement decision and cost with patients before recommending it as a first choice.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Pitolisant | Initial: Individualized titration schedule over about one month Maximum: 40 mg/day | Headache, insomnia, weight gain, anxiety | May reduce effectiveness of steroidal contraceptives | Not reimbursed by Canadian public drug plans per the December 2022 CDA-AMC (CADTH) recommendation; failed noninferiority to modafinil for EDS in the pivotal Canadian-reviewed trials; estimated cost approximately $6,074-$12,147/year |
Off-Label Anticataplectic Antidepressants
Widely used in practice given much faster onset than the oxybates and lower regulatory burden, but the AASM guideline made no formal recommendation for the SSRI/SNRI class specifically, citing insufficient/inconclusive trial-level evidence — set expectations with patients accordingly.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Venlafaxine | Adults: Individualized, low starting dose; titrate to effect | Nausea, hypertension, sexual dysfunction, discontinuation syndrome with abrupt cessation | Serotonin syndrome risk with other serotonergic drugs, including MAOIs (allow adequate washout) | The most commonly used off-label anticataplectic antidepressant in practice given rapid onset; taper rather than stop abruptly |
| Clomipramine | Adults: Individualized, low starting dose; titrate to effect | Anticholinergic effects (dry mouth, constipation, blurred vision), sedation, weight gain, cardiac conduction effects | Serotonin syndrome risk with other serotonergic drugs and MAOIs; additive anticholinergic/sedative burden with other such drugs | Historically the first agent used for cataplexy; greater anticholinergic and cardiac-conduction burden than venlafaxine, particularly relevant in older adults |
References
- Narcolepsy — CMAJ (Humphreys CJ, Liu RR, Simms TM). CMAJ 2024;196(1):E17
- Narcolepsy: Pathophysiology, Diagnosis, Management, and Future Directions — Brain and Behavior (Hastings et al.). Brain Behav 2025;15(12):e71116
- Sleep Disorders — CMA Driver's Guide, 10th edition — Determining Medical Fitness to Operate Motor Vehicles. CMA Driver's Guide, 10th ed., accessed 2026
- XYREM (sodium oxybate solution) Product Monograph — Jazz Pharmaceuticals Ireland Ltd. / Innomar Strategies Inc.. Date of Revision: September 29, 2022
- ALERTEC (modafinil) Product Monograph — Teva Canada Innovation. Date of Revision: May 26, 2023
- SUNOSI (solriamfetol tablets) Product Monograph — Jazz Pharmaceuticals Canada Inc.. Date of Initial Authorization: May 12, 2021
- RITALIN/RITALIN SR (methylphenidate hydrochloride) Product Monograph — Novartis Pharmaceuticals Canada Inc.. Revision Date: February 27, 2015
- Treatment of Central Disorders of Hypersomnolence: An American Academy of Sleep Medicine Clinical Practice Guideline — Journal of Clinical Sleep Medicine (Maski K, Trotti LM, Kotagal S, Auger RR, Rowley JA, Hashmi SD, Watson NF). J Clin Sleep Med 2021;17(9):1881-1893
- XYWAV (Calcium, Magnesium, Potassium, and Sodium Oxybates Solution) Product Monograph — Jazz Pharmaceuticals Ireland Ltd. / Innomar Strategies Inc.. Date of Authorization: July 24, 2024
- DEXEDRINE/DEXEDRINE SPANSULE (Dextroamphetamine Sulfate) Product Monograph — Paladin Pharma Inc.. Date of Revision: May 29, 2024
- Pitolisant Hydrochloride (Wakix): CADTH Reimbursement Recommendation — Canadian Drug Expert Committee, CDA-AMC (formerly CADTH). CADTH Reimbursement Recommendation, December 2022
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.